Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation

The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract in...

Full description

Saved in:
Bibliographic Details
Main Authors: Aliyeh Bazi, Seyed Mohammad Baghbanian, Monireh Ghazaeian, Sahar Fallah, Narjes Hendoiee
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2021/6616763
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546895333949440
author Aliyeh Bazi
Seyed Mohammad Baghbanian
Monireh Ghazaeian
Sahar Fallah
Narjes Hendoiee
author_facet Aliyeh Bazi
Seyed Mohammad Baghbanian
Monireh Ghazaeian
Sahar Fallah
Narjes Hendoiee
author_sort Aliyeh Bazi
collection DOAJ
description The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (p=560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (p≤0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.
format Article
id doaj-art-9efbf09539864571acc0feecad620219
institution Kabale University
issn 1712-9532
1918-1493
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-9efbf09539864571acc0feecad6202192025-02-03T06:46:44ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932021-01-01202110.1155/2021/66167636616763Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis ExacerbationAliyeh Bazi0Seyed Mohammad Baghbanian1Monireh Ghazaeian2Sahar Fallah3Narjes Hendoiee4Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IranDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, IranDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranThe first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (p=560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (p≤0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.http://dx.doi.org/10.1155/2021/6616763
spellingShingle Aliyeh Bazi
Seyed Mohammad Baghbanian
Monireh Ghazaeian
Sahar Fallah
Narjes Hendoiee
Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
Canadian Journal of Infectious Diseases and Medical Microbiology
title Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
title_full Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
title_fullStr Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
title_full_unstemmed Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
title_short Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation
title_sort evaluation of urinary tract infection following corticosteroid therapy in patients with multiple sclerosis exacerbation
url http://dx.doi.org/10.1155/2021/6616763
work_keys_str_mv AT aliyehbazi evaluationofurinarytractinfectionfollowingcorticosteroidtherapyinpatientswithmultiplesclerosisexacerbation
AT seyedmohammadbaghbanian evaluationofurinarytractinfectionfollowingcorticosteroidtherapyinpatientswithmultiplesclerosisexacerbation
AT monirehghazaeian evaluationofurinarytractinfectionfollowingcorticosteroidtherapyinpatientswithmultiplesclerosisexacerbation
AT saharfallah evaluationofurinarytractinfectionfollowingcorticosteroidtherapyinpatientswithmultiplesclerosisexacerbation
AT narjeshendoiee evaluationofurinarytractinfectionfollowingcorticosteroidtherapyinpatientswithmultiplesclerosisexacerbation